Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus - Test2 - elhamkhani - TriplyDB

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

http://www.wikidata.org/entity/Q27644501

about

Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop bNAber: database of broadly neutralizing HIV antibodies Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop HIV-1 prophylactic vaccines: state of the art HIV-Host Interactions: Implications for Vaccine Design Harnessing the protective potential of HIV-1 neutralizing antibodies The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination The evolution within us Recent strategies targeting HIV glycans in vaccine design Advances in structure-based vaccine design Structural insights on the role of antibodies in HIV-1 vaccine and therapy Designing synthetic vaccines for HIV Antibody responses to envelope glycoproteins in HIV-1 infection Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire HIV-1 neutralizing antibodies: understanding nature's pathways Host-pathogen interaction in HIV infection Antibodies in HIV-1 vaccine development and therapy Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection Virological features associated with the development of broadly neutralizing antibodies to HIV-1 HIV broadly neutralizing antibody targets Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains Progress in HIV-1 vaccine development.High-Throughput Sequencing-Based Immune Repertoire Study during Infectious Disease Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes

P2860

Q21559473-2507EBE5-BBE3-4E06-898D-2B5AF0C5625B Q24567758-18F19365-3082-4BD9-8A67-5E57EABA681A Q24598653-E4BE0AE8-D713-4164-87E3-809E323F9132 Q24616040-59745D7F-EA44-4F8D-82C1-C728FF6AF849 Q26740042-C12FD326-F92A-4421-82E8-81289094CB09 Q26765966-AE1C91C7-E891-4721-B1EA-F951E70DFD66 Q26766153-5E36AB52-3920-48BA-BEF8-63D7A48FED75 Q26767258-B5480E5B-981D-4D3F-AAEE-8E4EAB86243E Q26776518-A89D1BD0-7104-4C48-AF7A-210C37BD4B8E Q26801603-F487EE74-4831-44DE-B5AF-7BBA35FCE92F Q26823603-F3C317BE-19F5-4C52-80F8-E5CD949DDC96 Q26824545-F258AC93-7796-44D4-B98D-342F481E6368 Q26829461-52EDF2A4-EF1E-41D5-9A66-B23E10167B54 Q26862617-B3CD5DCC-A37B-49A3-A06C-FB5E36F95C9A Q26991572-2AEC6EFF-F156-4C52-BAE1-CF964506E66B Q26997997-63F16C12-84C6-4191-BB64-6657EB8CF73A Q27000480-26DF6783-8A6F-45D6-8C5C-075E610EBDE5 Q27009024-0680DA71-7422-49AF-BFD4-43E9A7148C29 Q27011574-41E9B83B-E77B-44FD-83CC-28F77ED23934 Q27022652-A57BEE15-5FDD-4912-A632-08E7FC49ABD8 Q27025177-DE9887B7-2472-472C-AA10-FA6A3C5632C6 Q27026662-76B0396E-1ECA-439E-B999-18FD2E91969D Q27319450-30459D1B-F8DB-4DD9-BBAF-8824DB105E84 Q27322403-FED01A6E-037B-4094-AA52-C7CEA562A658 Q27324184-DCFB91AA-EA40-4707-9767-E8B01DEC1CF4 Q27643993-A317168F-F487-4C1B-82D4-FBFF3E4C9227 Q27644383-BA26863A-8D56-4E5C-9C32-9B1A9317ED00 Q27644415-184396C5-F7AB-450F-A6F9-F59AEB7EBF92 Q27644515-4EEEFA3D-FAD8-4A62-B123-D2EB1249FEDE Q27654848-16BE8DC9-53FF-4655-A121-F5211B06E0AD Q27679353-1AADDE54-79B0-4BB9-9B9B-937F3A1F0BE0 Q27680497-274393A4-BA27-4FDF-B5EF-D089ED5CD483 Q27680688-2CD5CC9A-11B5-47C4-92B5-27F0C1DB983E Q27681806-63740A86-60D3-4385-A896-EDD2C47A6DE5 Q27684503-FC9388C3-6B28-417E-81EB-5EF344C61921 Q27693849-C5332469-28E4-43D7-A653-4E711B2BD210 Q28068214-C02E3C4A-596B-438A-8BCA-92FF0809A700 Q28075274-1A34C22C-8FAC-42ED-99BE-5BD46433B5F0 Q28084672-7496D99F-FCEA-4102-BEC1-1D49BF37A96A Q28271300-15AD65D8-407D-433D-93B6-2209ED9A281D

P2860

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

http://www.wikidata.org/entity/Q27644501

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@ast

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@en

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@nl

type

label

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@ast

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@en

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@nl

prefLabel

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@ast

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@en

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@nl

P1433

Q27644501-A8DBE8BB-1F3F-448E-8D70-8FA03A4240F0

P1476

Q27644501-7ADB4BF5-581A-45BD-95D4-9E0A78E7CC53

P2093

Q27644501-0A779405-C21E-4924-87B9-AE6115DB7492

Q27644501-0BB466D2-CD94-469A-9752-7A14CC78D140

Q27644501-1359BC1B-0408-4E69-BD84-8886A7F42E5F

Q27644501-1C4B5EAE-C28C-4EE7-9018-2F58BB3FA1E3

Q27644501-1FEEF41A-3B48-4414-B373-98AD555A2620

Q27644501-20786844-E5BB-4CEE-9949-CF58BDAC62BA

Q27644501-26AEF3DD-4C58-4AEA-801D-B64A91D91772

Q27644501-36DF637A-1A73-4E28-A201-DE49DE62743C

Q27644501-36E62384-AF0D-4D91-BC7B-9A38012FF00D

Q27644501-3933872F-96D1-443F-AF9B-A5CB66461029

P2860

Q27644501-0089925F-3A9F-4828-98F6-018EE8146D7E

Q27644501-072A5A36-6ACE-45C8-8644-CFEB9EA10689

Q27644501-261581D8-A2C5-4E0F-961F-B207BB2C4954

Q27644501-26D6F2B5-5BC4-43EC-AC9D-A5A2377E1722

Q27644501-2C15D4FE-D471-4BDC-B299-7893C1FF5E3D

Q27644501-30377F3D-96BB-4F0E-B28A-9994088AE5B3

Q27644501-35B8F8B8-862A-4181-B1B5-1DC979E78F2D

Q27644501-3A58FD81-CC0B-4A85-B331-54C4B3861D4D

Q27644501-3BCC0C56-49D6-4457-A641-39834A164A56

Q27644501-3D2524B4-1B95-4247-B1B9-9CC928413BA7

P2888

Q27644501-35E384D1-331A-4E9D-B53C-BDD862F98E29

P304

Q27644501-637FAD57-A9F6-4F5F-9CF0-2B7B538408AC

P31

Q27644501-23D3D5FC-7D8B-4D0F-B03F-89C70CA1298B

P3181

Q27644501-26FCD1B8-D24E-4BDD-B1BC-13F38D6DA4BA

P356

Q27644501-7EDE052C-C159-4445-A67F-3A8CDCCA7835

P407

Q27644501-9D834026-EB37-427E-841E-33424F200A3F

P433

Q27644501-9173462E-EAE0-435A-9E50-3A5FBC4C1980

P478

Q27644501-2290BE63-CA83-465B-B34F-724D573B79F3

P50

Q27644501-02A86CDB-4D4D-4B75-9DF0-2E847A334A64

Q27644501-04B9F218-C2E5-433B-91C6-096EE1C7DA21

Q27644501-184076B3-17F7-404E-8B96-36213D390F62

Q27644501-40338D07-BC02-41FA-AF8B-A660E1D1CCBF

Q27644501-72DC48EF-16D6-4CDE-9690-4AF46E6A11E6

Q27644501-7BA36CCB-1052-42B6-96F7-9CD77AB53121

Q27644501-860963D1-5F67-4226-B0C4-B7452052D617

Q27644501-8CC0C848-38F9-4013-8E9F-B13DB87C44B8

Q27644501-B2649141-DAA6-4957-A1B9-D6ACB96A9D85

Q27644501-D3FC1BA4-99D7-4434-978E-28427720227E

P577

Q27644501-E88460E6-3C88-4672-821B-09D23C458BB3

P5875

Q27644501-26A5DD83-71C2-49D2-BFD8-A3E334C80EDD

P6179

Q27644501-143A1611-0E9B-4E3C-A4B0-25B0CD3C6E21

P698

Q27644501-1A70BE93-53CF-424B-8ED9-4DCFC9E8701D

P921

Q27644501-587C06C6-4A3A-45A0-BC86-AA7D9B7582F2

Q27644501-C99FC041-7200-4A4F-91F9-DAE7B3F4DA2A

Q27644501-F22E2AE3-7E0D-4D8C-A236-ACE8CA83322A

P932

Q27644501-9DBAE378-5F57-4C0F-B869-FEFE519119E9

P3181

P356

P1433

P1476

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

@en

P2093

Andrew Z Fire

http://www.w3.org/2001/XMLSchema#string

Anqi Zheng

http://www.w3.org/2001/XMLSchema#string

Baoshan Zhang

http://www.w3.org/2001/XMLSchema#string

Bette T M Korber

http://www.w3.org/2001/XMLSchema#string

Chaim A Schramm

http://www.w3.org/2001/XMLSchema#string

Fangping Cai

http://www.w3.org/2001/XMLSchema#string

Feng Gao

http://www.w3.org/2001/XMLSchema#string

Gift Kamanga

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Hua-Xin Liao

http://www.w3.org/2001/XMLSchema#string

P2860

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

Therapeutic antibodies, vaccines and antibodyomes

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals

MolProbity: all-atom contacts and structure validation for proteins and nucleic acids

pdb-care (PDB carbohydrate residue check): a program to support annotation of complex carbohydrate structures in PDB files

Processing of X-ray diffraction data collected in oscillation mode

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

P2888

P304

469-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

822033

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE12053

http://www.w3.org/2001/XMLSchema#string

P407

P433

7446

http://www.w3.org/2001/XMLSchema#string

P478

496

http://www.w3.org/2001/XMLSchema#string

P50

Lawrence Shapiro

Stephanie Moquin

Peter T. Hraber

Thomas B. Kepler

Beatrice H. Hahn

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236103892

http://www.w3.org/2001/XMLSchema#string

P6179

1020216641

http://www.w3.org/2001/XMLSchema#string

P698

23552890

http://www.w3.org/2001/XMLSchema#string

P921

P932

3637846

http://www.w3.org/2001/XMLSchema#string